

**Date:** 10 September, 2025

To,  
**National Stock Exchange of India Limited,**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (E), Mumbai – 400051

**Subject: Clarification on Financial Results for the quarter ended 30<sup>th</sup> June, 2025**

Dear Sir/Madam,

This is with reference to your email dated 8<sup>th</sup> September, 2025 regarding clarification on financial results submitted by the Company for the quarter ended 30<sup>th</sup> June, 2025. In this regard, we would like to submit as follows:

**1. Authorization for signing of Financial Results:**

The Board of Directors of the Company has duly authorized any Director of the Company in absence of Managing Director for signing the Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2025. Accordingly, please find enclosed herewith extract of resolution passed in Board Meeting evidencing the said authorization in **Annexure 1**.

**2. Discrepancy in XBRL submission:**

Due to an inadvertent typographical error, the face value mentioned in the XBRL file was incorrectly stated. The same has now been rectified and we are enclosing herewith the corrected XBRL file for your records and necessary updation.

We sincerely regret the inconvenience caused and request you to kindly update your records accordingly.

Thanking you,  
Yours faithfully,

For **JHS Svendgaard Laboratories Limited**

**KOMAL** Digitally signed  
by KOMAL JHA  
**JHA** Date: 2025.09.10  
11:59:03 +05'30'

**Komal Jha**

**Company Secretary and Compliance Officer**

**Encl.: A/a**

1. Extract of Board Resolution
2. Corrected XBRL file

**CERTIFIED TRUE COPY OF THE RESOLUTION PASSED IN THE 05<sup>th</sup> MEETING OF THE BOARD OF DIRECTORS FOR FINANCIAL YEAR 2025-26 OF JHS SVENDGAARD LABORATORIES LIMITED HELD ON TUESDAY, 12<sup>TH</sup> AUGUST, 2025 AT 03:50 P.M. AT CORPORATE OFFICE OF THE COMPANY AT B-1/E-23, MOHAN CO-OPERATIVE INDUSTRIAL AREA, MATHURA ROAD, NEW DELHI-110044.**

---

**CONSIDER AND APPROVE THE UN-AUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2025 AND TAKE ON RECORD, THE LIMITED REVIEW REPORTS GIVEN BY THE AUDITORS OF THE COMPANY AND APPROVE THE PUBLICATION OF THE FINANCIAL RESULTS UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.**

**“RESOLVED THAT** pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, if any, of the Companies Act, 2013, the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2025, recommended by the Audit Committee, and placed before the Board, be and are hereby considered, approved, and taken on record.

**RESOLVED FURTHER THAT** the Limited Review Reports on the said financial results as submitted by the Statutory Auditors of the Company be and are hereby noted and taken on record.

**RESOLVED FURTHER THAT** Mr. Nikhil Nanda, Managing Director or in the absence of the Managing Director, any other Director of the Company be and is hereby authorized to sign the aforesaid Un-Audited Financial Results for and on behalf of the Board to transmit the same to the concerned stock exchanges and to publish the same in newspapers as prescribed, and take such further actions as may be necessary or expedient in this regard.”

**For and on Behalf of  
JHS Svendgaard Laboratories Limited**

**NIKHIL** Digitally signed by  
NIKHIL NANDA  
**NANDA** Date: 2025.09.09  
16:32:39 +05'30'

**Nikhil Nanda  
Managing Director  
DIN: 00051501**

**Date:** 09 September, 2025

**Place:** New Delhi

### General information about company

Scrip code*	532771
NSE Symbol*	JHS
MSEI Symbol*	NOTLISTED
ISIN*	INE544H01014
Name of company	JHS Svendgaard Laboratories Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	12-08-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	07-08-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	oral care manufacturing
Start date and time of board meeting	12-08-2025 15:50
End date and time of board meeting	12-08-2025 16:46
Whether cash flow statement is applicable on company	
Type of cash flow statement	

Declaration of unmodified opinion or statement on impact of audit qualification		Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		Yes
No. of times funds raised during the quarter		1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Not Defaulted was made during the Quarther

<b>Financial Results – Ind-AS</b>				
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>	
Date of start of reporting period		01-04-2025	01-04-2025	
Date of end of reporting period		30-06-2025	30-06-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Standalone	Standalone	
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>			
<b>1</b>	<b>Income</b>			
	Revenue from operations	2345.41	2345.41	
	Other income	99.83	99.83	
	<b>Total income</b>	<b>2445.24</b>	<b>2445.24</b>	
<b>2</b>	<b>Expenses</b>			
(a)	Cost of materials consumed	1421.83	1421.83	
(b)	Purchases of stock-in-trade	9.72	9.72	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-41.64	-41.64	
(d)	Employee benefit expense	266.53	266.53	
(e)	Finance costs	15.67	15.67	
(f)	Depreciation, depletion and amortisation expense	187.61	187.61	
(g)	<b>Other Expenses</b>			
1	Other Expenses	288.25	288.25	
2	Power & Fuel	103.17	103.17	
3	Rent	20.75	20.75	

4	Repair & Maintenance	75.94	75.94
5	Legal & Professional	34.59	34.59
	<b>Total other expenses</b>	<b>522.7</b>	<b>522.7</b>
	<b>Total expenses</b>	<b>2382.42</b>	<b>2382.42</b>
3	<b>Total profit before exceptional items and tax</b>	<b>62.82</b>	<b>62.82</b>
4	Exceptional items	0	0
5	<b>Total profit before tax</b>	<b>62.82</b>	<b>62.82</b>
6	<b>Tax expense</b>		
7	Current tax	0	0
8	Deferred tax	-42.75	-42.75
9	<b>Total tax expenses</b>	<b>-42.75</b>	<b>-42.75</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	<b>Net Profit Loss for the period from continuing operations</b>	<b>105.57</b>	<b>105.57</b>
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0</b>	<b>0</b>
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	<b>Total profit (loss) for period</b>	<b>105.57</b>	<b>105.57</b>
17	<u>Other comprehensive income net of taxes</u>	2.19	2.19
18	<b>Total Comprehensive Income for the period</b>	<b>107.76</b>	<b>107.76</b>
19	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent		

	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	8560.4	8560.4	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	0.12	0.12	
	Diluted earnings (loss) per share from continuing operations	0.12	0.12	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	0.12	0.12	
	Diluted earnings (loss) per share from continuing and discontinued operations	0.12	0.12	
24	Debt equity ratio			Textual Information( 1)
25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)		

Other Comprehensive Income			
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Items that will not be reclassified to profit or loss	2.96	2.96
	Total Amount of items that will not be reclassified to profit and loss	2.96	2.96
2	Income tax relating to items that will not be reclassified to profit or loss	0.77	0.77
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	2.19	2.19



<b>Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)</b>	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	04-06-2024
Amount Raised	2999.99
Report filed for Quarter ended	30-06-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	Yes
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Yes
If Yes, Date of shareholder Approval	23-06-2025
Explanation for the Deviation / Variation	Object of Prefrential issue has been modified with the approval of shareholders.
Comments of the Audit Committee after review	
Comments of the auditors, if any	

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	For Setting Up new Project in Jammu & Kashmir under Industrial Development Scheme(IDS) 2021-2030, J & K	Fund the capital expenditure for acquiring equipment for manufacturing facility	2249.99	599.99	134.29	1650	
2	For General Corporate Purpose	NA	750	0	749.5	0	
3	NIL	Infusion of funds in Group entity i.e. JHS Svendgaard Retail Ventures Ltd., for funding the expansion plan through strategic fund infusion	0	1650	0	1650	

Signatory Details	
Name of signatory	Ashish Goel
Designation of person	Chief Financial Officer
Place	New Delhi
Date	12-08-2025



### General information about company

Scrip code*	532771
NSE Symbol*	JHS
MSEI Symbol*	NOTLISTED
ISIN*	INE544H01014
Name of company	JHS Svendgaard Laboratories Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	12-08-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	07-08-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	oral care manufacturing
Start date and time of board meeting	12-08-2025 15:50
End date and time of board meeting	12-08-2025 16:46
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

<b>Financial Results – Ind-AS</b>				
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>	
Date of start of reporting period		01-04-2025	01-04-2025	
Date of end of reporting period		30-06-2025	30-06-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Consolidated	Consolidated	
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>			
<b>1</b>	<b>Income</b>			
	Revenue from operations	2345.41	2345.41	
	Other income	99.83	99.83	
	<b>Total income</b>	<b>2445.24</b>	<b>2445.24</b>	
<b>2</b>	<b>Expenses</b>			
(a)	Cost of materials consumed	1421.83	1421.83	
(b)	Purchases of stock-in-trade	9.72	9.72	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-41.64	-41.64	
(d)	Employee benefit expense	266.53	266.53	
(e)	Finance costs	15.67	15.67	
(f)	Depreciation, depletion and amortisation expense	187.61	187.61	
<b>(g)</b>	<b>Other Expenses</b>			
1	Other Expenses	288.29	288.29	
2	Power & Fuel	103.17	103.17	
3	Rent	20.75	20.75	

4	Repair & Maintenance	75.94	75.94
5	Legal & Professional	34.59	34.59
	<b>Total other expenses</b>	<b>522.74</b>	<b>522.74</b>
	<b>Total expenses</b>	<b>2382.46</b>	<b>2382.46</b>
3	<b>Total profit before exceptional items and tax</b>	<b>62.78</b>	<b>62.78</b>
4	Exceptional items	0	0
5	<b>Total profit before tax</b>	<b>62.78</b>	<b>62.78</b>
6	<b>Tax expense</b>		
7	Current tax	0	0
8	Deferred tax	-42.74	-42.74
9	<b>Total tax expenses</b>	<b>-42.74</b>	<b>-42.74</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	<b>Net Profit Loss for the period from continuing operations</b>	<b>105.52</b>	<b>105.52</b>
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0</b>	<b>0</b>
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	<b>Total profit (loss) for period</b>	<b>105.52</b>	<b>105.52</b>
17	<u>Other comprehensive income net of taxes</u>	2.19	2.19
18	<b>Total Comprehensive Income for the period</b>	<b>107.71</b>	<b>107.71</b>
19	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent	105.52	105.52
	Total profit or loss, attributable to non-controlling interests		
20	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	107.72	107.72

	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	8560.4	8560.4	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	0.12	0.12	
	Diluted earnings (loss) per share from continuing operations	0.12	0.12	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	0.12	0.12	
	Diluted earnings (loss) per share from continuing and discontinued operations	0.12	0.12	
24	Debt equity ratio			Textual Information( 1)
25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)		



Other Comprehensive Income			
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Items that will not be reclassified to profit or loss	2.96	2.96
	Total Amount of items that will not be reclassified to profit and loss	2.96	2.96
2	Income tax relating to items that will not be reclassified to profit or loss	0.77	0.77
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	2.19	2.19

